EGFR and non-small cell lung carcinoma: Furthermore, Yun et al. suggested the potential use of melatonin and gefitinib in NSCLC patients with epidermal growth factor receptor (EGFR) mutations (T790M) resistant to tyrosine kinase inhibitors [36].